Pharma News – January 13, 2020

Your weekly dose of interesting tidbits from around the pharma web…


Big retailers and health-care companies are using technology to improve primary care services. CVS recently announced plans to roll out 1,500 new enhanced in-store clinics over the next 24 months that will offer check-ups, testing services, and nutritional and health counseling. Walmart, which already operates Care Clinics in Georgia, Texas and South Carolina offering doctor visits, lab and x-ray services, has plans to further expand services into dental, counseling and even fitness across a larger number of store locations. (CNBC)


23andMe has inked a deal with Spanish pharma company Almirall to license an antibody identified by 23andMe. Almirall plans to use the monoclonal antibodies 23andMe identified through research to develop a dermatology treatment. As part of the agreement (whose financial terms were undisclosed), Almirall secured the rights to develop and commercialize the antibody for use in treatments worldwide. This is 23andMe’s first drug development deal, opening up another use for the genetic data it has collected. (TechCrunch)


Lilly to acquire Dermira, a small biotech developing drugs for chronic skin conditions for $1.1 billion. The main focus of the deal is the drug lebrikizumab designed to treat people suffering from moderate-to-severe atopic dermatitis, the most common form of eczema. Dermira shares, which doubled in the last month, rose 5.1% over the offer price making some investors question if another bidder might set up for Dermira. (Reuters)


California could become the first state to launch its own generic prescription drug label under a new proposal by Gov. Gavin Newsom. Newsom wants California to contract with generic drug companies on its behalf so the state could then sell them to the public. The goal is to lower prices by increasing competition in the generic market. State lawmakers must approve the plan which is part of Newsom’s forthcoming budget proposal. (NBCNews)


Building meaningful relationships with HCPs is key to pharmaceutical sales success, and so it’s crucial for medcomm agencies. Check out our latest blog “Increasing HCP Engagement Through Speaker Program Technology” for some helpful tips on how you can start using speaker program technology to increase engagement with HCPs and pharma for better program ROI.


–  To find out more about Pharmagin, Contact Us  –